| Browse All

Olema Pharmaceuticals, Inc. (OLMA)

Healthcare | Biotechnology | San Francisco, United States | NasdaqGS
16.58 USD -0.24 (-1.427%) ⇩ (April 20, 2026, 4 p.m. EDT)

Short-term: ★★★★☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:23 a.m. EDT

Olema is trading at a technical inflection point where risk-averse capital has established a $25 mask via heavy call OI, while the recent 33% downward trend likely has reached over-extended territory. The skewed options distribution for May 2026 implies an asymmetric bet on upside movement to test resistance, despite the stock remaining in bear territory (R=1) due to negative earnings and lack of dividend history.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.298626
AutoTheta0.321398
AutoETS0.321749
AutoARIMA0.336548

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 41%
H-stat 69.37
Ljung-Box p 0.000
Jarque-Bera p 0.050
Excess Kurtosis -1.78
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.876
Market Cap 1,445,062,400
Forward P/E -6.52
Beta 2.18
Website https://olema.com

As of April 19, 2026, 12:23 a.m. EDT: Options activity shows a clear bullish bias for the near term. The May 2026 call chain has massive Open Interest (OI) at 30.0 ($3.6k) and 25.0 ($136) strikes, suggesting a price ceiling expectation between $25-$30. Conversely, put volume and OI are heavily concentrated below $17, with significant protection buying at 14.0 and below in the July 2026 table. This structure indicates speculators are positioning for a rebound from current levels ($16.82), betting on the 30.0 strike being the primary resistance, while selling deep out-of-the-money puts to support a potential upside move.


Info Dump

Attribute Value
52 Week Change 2.342742
Address1 780 Brannan Street
All Time High 60.27
All Time Low 2.0
Ask 16.65
Ask Size 1
Audit Risk 5
Average Daily Volume10 Day 868,810
Average Daily Volume3 Month 1,600,600
Average Volume 1,600,600
Average Volume10Days 868,810
Beta 2.182
Bid 16.5
Bid Size 1
Board Risk 8
Book Value 5.881
City San Francisco
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 10
Country United States
Crypto Tradeable 0
Currency USD
Current Price 16.58
Current Ratio 9.95
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 17.465
Day Low 16.31
Debt To Equity 0.876
Display Name Olema Pharmaceuticals
Earnings Timestamp 1,773,664,200
Earnings Timestamp End 1,778,589,000
Earnings Timestamp Start 1,778,589,000
Ebitda -168,208,000
Ebitda Margins 0.0
Enterprise To Ebitda -5.611
Enterprise Value 943,818,432
Eps Current Year -2.28745
Eps Forward -2.5439
Eps Trailing Twelve Months -1.87
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 18.646
Fifty Day Average Change -2.066
Fifty Day Average Change Percent -0.11080124
Fifty Two Week Change Percent 234.2742
Fifty Two Week High 36.259
Fifty Two Week High Change -19.678999
Fifty Two Week High Change Percent -0.5427342
Fifty Two Week Low 3.89
Fifty Two Week Low Change 12.69
Fifty Two Week Low Change Percent 3.2622106
Fifty Two Week Range 3.89 - 36.259
Financial Currency USD
First Trade Date Milliseconds 1,605,796,200,000
Float Shares 67,426,368
Forward Eps -2.5439
Forward P E -6.517552
Free Cashflow -82,896,248
Full Exchange Name NasdaqGS
Full Time Employees 131
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.01972
Held Percent Institutions 1.01128
Implied Shares Outstanding 87,156,961
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,020-11-19
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Long Name Olema Pharmaceuticals, Inc.
Market us_market
Market Cap 1,445,062,400
Market State PRE
Max Age 86,400
Message Board Id finmb_540573682
Most Recent Quarter 1,767,139,200
Net Income To Common -162,451,008
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,445,062,413
Number Of Analyst Opinions 11
Open 16.79
Operating Cashflow -146,716,000
Operating Margins 0.0
Overall Risk 9
Payout Ratio 0.0
Phone 415 651 3316
Pre Market Change 0.049999237
Pre Market Change Percent 0.30156356
Pre Market Price 16.63
Pre Market Time 1,776,769,083
Previous Close 16.82
Price Eps Current Year -7.2482457
Price Hint 2
Price To Book 2.8192484
Profit Margins 0.0
Quick Ratio 9.835
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.24
Regular Market Change Percent -1.42687
Regular Market Day High 17.465
Regular Market Day Low 16.31
Regular Market Day Range 16.31 - 17.465
Regular Market Open 16.79
Regular Market Previous Close 16.82
Regular Market Price 16.58
Regular Market Time 1,776,715,200
Regular Market Volume 1,142,669
Return On Assets -0.21420999
Return On Equity -0.36608002
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 87,156,961
Shares Percent Shares Out 0.1407
Shares Short 12,265,390
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 8,257,215
Short Name Olema Pharmaceuticals, Inc.
Short Percent Of Float 0.1516
Short Ratio 5.19
Source Interval 15
State CA
Symbol OLMA
Target High Price 62.0
Target Low Price 27.0
Target Mean Price 43.0
Target Median Price 40.0
Total Cash 505,436,992
Total Cash Per Share 5.799
Total Debt 4,193,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.87
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 15.39885
Two Hundred Day Average Change 1.1811495
Two Hundred Day Average Change Percent 0.07670374
Type Disp Equity
Volume 1,142,669
Website https://olema.com
Zip 94,103